BCL2 and triple-negative breast carcinoma: In the present study, we have demonstrated that eIF4E induced cisplatin-resistance in ESCC mainly by promoting PI3K/AKT pathway and increasing Bcl-2/Bax ratio, which is similar to eIF4E in triple-negative breast cancer cells [18].